Physician profile
Narayanan Krishnamoorthy
NPI 1184817967
$4,664.25
in general payments reported to CMS, 2019-2025
30 companies · $762 in 2025
The $762 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $537 · 2021: $485 · 2022: $601 · 2023: $836 · 2024: $641 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,220.35 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $845.98 | 2019-2025 | Apligraf, Affinity, Puraply |
| Astrazeneca Pharmaceuticals LP | $424.29 | 2020-2023 | Farxiga |
| Abbvie INC. | $414.93 | 2021-2025 | |
| Amgen INC. | $322.37 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $274.65 | 2019-2024 | |
| Smith+Nephew, INC. | $272.32 | 2019-2025 | Collagenase Santyl, Allevyn Heel 10.5cm X 13.5cm Ctn 5, Acticoat 4" X 4" |
| Silk Road Medical, INC. | $260.64 | 2021-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Lilly USA, LLC | $219.12 | 2020-2023 | Mounjaro |
| Kerecis Limited | $174.90 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Bayer Healthcare Pharmaceuticals INC. | $147.59 | 2022-2024 | |
| Pfizer INC. | $146.77 | 2020-2023 | |
| Stryker Corporation | $139.58 | 2025 | Limflow System |
| Intuitive Surgical, INC. | $125.53 | 2025 | |
| Cardiovascular Systems INC. | $110.57 | 2019 | |
| Integra Lifesciences Corporation | $110.15 | 2019-2025 | Tcc-Ez |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $92.16 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $83.90 | 2019 | |
| Merck Sharp & Dohme LLC | $78.96 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $74.62 | 2022 | |
| Allergan, INC. | $73.56 | 2019 | |
| Misonix INC | $60.00 | 2021 | |
| Novo Nordisk INC | $53.46 | 2023-2024 | Rybelsus, Ozempic |
| Convatec INC. | $37.93 | 2022-2024 | |
| Triad Life Sciences INC. | $37.53 | 2022 | |
| Bioventus LLC | $27.91 | 2023 | |
| Paratek Pharmaceuticals, INC. | $15.48 | 2025 | Nuzyra |
| Abbott Laboratories | $13.35 | 2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $12.41 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $11.50 | 2019 | |
| Astellas Pharma US INC | $2.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayanan Krishnamoorthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.